Halozyme Therapeutics, Inc. / Analyst ratings
Price targets
Analyst ratings
No analyst ratings available
-
PMorgan: Big differences between Halozyme and Evotec
NEW YORK (dpa-AFX Analyst) - In light of the interest in Evotec, US bank JPMorgan has maintained its rating for Halozyme at "Neutral" with a price target of $54. Analyst Jessica Fye, in a study published Friday, believes that the American company sees the potential to build a powerful, diversified service offering with the drug discovery company. This move likely comes as a surprise to investors. Given the significant differences between Evotec and Halozyme, they believe it will take some time for the market to consider the implications of such a deal./tih/ajx
Publication of the original study: November 15, 2024 / 12:38 PM / EST
First distribution of the original study: November 15, 2024 / 12:38 PM / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.